The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2009

Filed:

Feb. 03, 2006
Applicants:

Takashi Yamamoto, Kawasaki, JP;

Akira Chiba, Kawasaki, JP;

Koichi Fujita, Kawasaki, JP;

Yuka Kataba, Kawasaki, JP;

Koji Ohsumi, Kawasaki, JP;

Sayaka Asari, Kawasaki, JP;

Naoyuki Fukuchi, Kawasaki, JP;

Misato Noguchi, Kawasaki, JP;

Itsuya Tanabe, Kawasaki, JP;

Chiori Ijichi, Kawasaki, JP;

Naoko Oomuta, Kawasaki, JP;

Yuko Iida, Kawasaki, JP;

Satoshi Iwayama, Kawasaki, JP;

Inventors:

Takashi Yamamoto, Kawasaki, JP;

Akira Chiba, Kawasaki, JP;

Koichi Fujita, Kawasaki, JP;

Yuka Kataba, Kawasaki, JP;

Koji Ohsumi, Kawasaki, JP;

Sayaka Asari, Kawasaki, JP;

Naoyuki Fukuchi, Kawasaki, JP;

Misato Noguchi, Kawasaki, JP;

Itsuya Tanabe, Kawasaki, JP;

Chiori Ijichi, Kawasaki, JP;

Naoko Oomuta, Kawasaki, JP;

Yuko Iida, Kawasaki, JP;

Satoshi Iwayama, Kawasaki, JP;

Assignee:

Ajinomoto Co., Inc., Tokyo, JP;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 261/04 (2006.01); A01N 43/80 (2006.01);
U.S. Cl.
CPC ...
Abstract

Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.


Find Patent Forward Citations

Loading…